NCT03993873: A trial that was reported late by Turning Point Therapeutics, Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03993873 |
|---|---|
| Title | A Phase 1/2 of Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of TPX-0022 in Adult Subjects With Locally Advanced or Metastatic NSCLC, Gastric Cancer, or Solid Tumors Harboring Genetic Alterations in MET |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 21, 2019 |
| Completion date | March 2, 2025 |
| Required reporting date | March 2, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Jan. 17, 2025 |
| Days late | None |